367 related articles for article (PubMed ID: 36680084)
21. Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy.
Wächter C; Eiden LE; Naumann N; Depboylu C; Weihe E
J Neuroinflammation; 2016 Oct; 13(1):272. PubMed ID: 27737697
[TBL] [Abstract][Full Text] [Related]
22. Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV.
Matt SM; Nickoloff-Bybel EA; Rong Y; Runner K; Johnson H; O'Connor MH; Haddad EK; Gaskill PJ
Front Immunol; 2021; 12():663061. PubMed ID: 34093554
[TBL] [Abstract][Full Text] [Related]
23. The Effects of Opioids on HIV Neuropathogenesis.
Murphy A; Barbaro J; Martínez-Aguado P; Chilunda V; Jaureguiberry-Bravo M; Berman JW
Front Immunol; 2019; 10():2445. PubMed ID: 31681322
[TBL] [Abstract][Full Text] [Related]
24. HIV and drug abuse mediate astrocyte senescence in a β-catenin-dependent manner leading to neuronal toxicity.
Yu C; Narasipura SD; Richards MH; Hu XT; Yamamoto B; Al-Harthi L
Aging Cell; 2017 Oct; 16(5):956-965. PubMed ID: 28612507
[TBL] [Abstract][Full Text] [Related]
25. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.
Crowell CS; Malee KM; Yogev R; Muller WJ
Rev Med Virol; 2014 Sep; 24(5):316-31. PubMed ID: 24806816
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of CNS Viral Seeding by HIV
Veenstra M; León-Rivera R; Li M; Gama L; Clements JE; Berman JW
mBio; 2017 Oct; 8(5):. PubMed ID: 29066542
[TBL] [Abstract][Full Text] [Related]
27. Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.
Rosenthal J; Tyor W
J Neurovirol; 2019 Oct; 25(5):673-685. PubMed ID: 30868422
[TBL] [Abstract][Full Text] [Related]
28. HIV life cycle, innate immunity and autophagy in the central nervous system.
Meulendyke KA; Croteau JD; Zink MC
Curr Opin HIV AIDS; 2014 Nov; 9(6):565-71. PubMed ID: 25203639
[TBL] [Abstract][Full Text] [Related]
29. The Impact of COVID-19 on People Living with HIV-1 and HIV-1-Associated Neurological Complications.
Dutta D; Liu J; Xiong H
Viruses; 2023 May; 15(5):. PubMed ID: 37243203
[TBL] [Abstract][Full Text] [Related]
30. HIV Infection and Neurocognitive Disorders in the Context of Chronic Drug Abuse: Evidence for Divergent Findings Dependent upon Prior Drug History.
Illenberger JM; Harrod SB; Mactutus CF; McLaurin KA; Kallianpur A; Booze RM
J Neuroimmune Pharmacol; 2020 Dec; 15(4):715-728. PubMed ID: 32533296
[TBL] [Abstract][Full Text] [Related]
31. Role of the inflammasomes in HIV-associated neuroinflammation and neurocognitive disorders.
Katuri A; Bryant J; Heredia A; Makar TK
Exp Mol Pathol; 2019 Jun; 108():64-72. PubMed ID: 30922769
[TBL] [Abstract][Full Text] [Related]
32. The impact of HIV-1 on neurogenesis: implications for HAND.
Ferrell D; Giunta B
Cell Mol Life Sci; 2014 Nov; 71(22):4387-92. PubMed ID: 25134912
[TBL] [Abstract][Full Text] [Related]
33. Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.
Matt SM; Gaskill PJ
Brain Res; 2019 Nov; 1723():146398. PubMed ID: 31442412
[TBL] [Abstract][Full Text] [Related]
34. HIV-associated neurological disorders: a guide to pharmacotherapy.
Tan IL; McArthur JC
CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity.
Mahajan SD; Aalinkeel R; Parikh NU; Jacob A; Cwiklinski K; Sandhu P; Le K; Loftus AW; Schwartz SA; Quigg RJ; Alexander JJ
Immunol Invest; 2017 Nov; 46(8):816-832. PubMed ID: 29058550
[TBL] [Abstract][Full Text] [Related]
36. PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation.
Roberts TK; Eugenin EA; Morgello S; Clements JE; Zink MC; Berman JW
Am J Pathol; 2010 Oct; 177(4):1848-60. PubMed ID: 20724601
[TBL] [Abstract][Full Text] [Related]
37. Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).
Kolson DL
Curr HIV/AIDS Rep; 2022 Oct; 19(5):344-357. PubMed ID: 35867211
[TBL] [Abstract][Full Text] [Related]
38. The Endocannabinoid System as a Potential Therapeutic Target for HIV-1-Associated Neurocognitive Disorder.
Chu L; Shu Z; Gu X; Wu Y; Yang J; Deng H
Cannabis Cannabinoid Res; 2023 Jun; 8(3):445-463. PubMed ID: 36745405
[No Abstract] [Full Text] [Related]
39. Human Immunodeficiency Virus Type 1 gp120 and Tat Induce Mitochondrial Fragmentation and Incomplete Mitophagy in Human Neurons.
Teodorof-Diedrich C; Spector SA
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158296
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory Mechanisms and Cascades Contributing to Neurocognitive Impairment in HIV/AIDS.
Fernandes N; Pulliam L
Curr Top Behav Neurosci; 2021; 50():77-103. PubMed ID: 31385260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
